Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger
Japan firms up proposals for expanded cost-effectiveness assessment scheme for selected drugs and devices after a policy committee outlines plans that could see associated price adjustments for reviewed products.
You may also be interested in...
Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.